Novartis is championing patient access to radioligand therapy (RLT)
The only company with 2 FDA-approved RLTs used to treat ~50,000 patients across 3 indications in multiple tumor types1-4
Learn more about the Novartis RLTs currently available to patients
Novartis brought the first RLT to market in 2018 and since then ~50,000 patients have been treated2-4
Access to RLT is accelerating rapidly
RLT treatment sites have seen a ~7x increase over the past 8 years, expanding access to patients who need it most5
 |
90% of eligible RLT patients are located within 30 miles of a treatment site6,7
3 active Novartis RLT manufacturing sites are currently operating in the US, with 2 additional sites planned8
Novartis RLT manufacturing sites have a production capacity of >250,000 doses8
 |
Novartis products are delivered to treatment sites within 5 days of order placement9,10
Novartis is applying cutting-edge innovation to RLT manufacturing and supply chain excellence
Watch the video to learn more about the manufacturing of RLT and the dedication of our teams around the world
Why geography shouldn’t limit cancer care: The growing reach of RLT
References: 1. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp. 2. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp. 3. Data on file. PLUVICTO NPS Metrics. Novartis Pharmaceuticals Corp; 2026. 4. Data on file. LUTATHERA ROME extract. Novartis Pharmaceuticals Corp; December 2025. 5. Data on file. Pluvicto and Lutathera site opening summary. Novartis Pharmaceuticals Corp; 2026. 6. Data on file. Patient location. Novartis Pharmaceuticals Corp; 2025. 7. Data on file. Pluvicto desert analysis. Novartis Pharmaceuticals Corp; 2025. 8. Data on file. Novartis manufacturing site openings summary. Novartis Pharmaceuticals Corp; 2026. 9. Data on file. Novartis on-time delivery. Novartis Pharmaceuticals Corp; 2024. 10. Novartis. Novartis growth story. Presented at JP Morgan Healthcare Conference, January 14, 2025.